iShares Biotechnology ETF
IBB
IBB
631 hedge funds and large institutions have $6.3B invested in iShares Biotechnology ETF in 2018 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 195 increasing their positions, 209 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
631
Holders Change
+22
Holders Change %
+3.61%
% of All Funds
14.45%
Holding in Top 10
22
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.35%
% of All Funds
0.5%
New
73
Increased
195
Reduced
209
Closed
46
Calls
$379M
Puts
$654M
Net Calls
-$276M
Net Calls Change
-$191M
Top Buyers
| 1 |
DFO
Duquesne Family Office
New York
|
$126M |
| 2 |
Two Sigma Investments
New York
|
$42.6M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
$236M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
$27.4M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
$89.9M |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$230M |
| 2 |
Goldman Sachs
New York
|
$259M |
| 3 |
UBS Group
Zurich,
Switzerland
|
$440M |
| 4 |
N
Natixis
Paris,
France
|
$91.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
$1.72B |
